All In Biotech

Drug Trial Radar · NCT07450482

Safety and Efficacy of JKN2304 Inhalation Solution in Patients With Moderate to Severe COPD

A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled (Open-Label), Phase IIa Clinical Study to Evaluate the Safety and Efficacy of JKN2304 Inhalation Solution in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Last checked: Nov 19, 2026Latest source record: Mar 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

42

Actual

Start

Jul 22, 2025

Primary completion

Sep 25, 2025

Study completion Sep 25, 2025

Sponsor

Sponsor type
Industry
Collaborators
Livzon Pharmaceutical Group Inc.
First posted
Mar 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 40 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this Phase IIa study is to evaluate the safety, efficacy, and pharmacokinetics of JKN2304 Inhalation Solution in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD). The study is a multicenter, randomized, double-blind, placebo-controlled, and active-controlled (open-label) trial. Participants are randomized to receive JKN2304 (2 mg once daily or 2 mg twice daily), Placebo, or Formoterol Fumarate Inhalation Solution for a treatment period of 14 days.

Conditions

  • COPD (Chronic Obstructive Pulmonary Disease)
  • COPD

Interventions

  • JKN2304 Inhalation SolutionDrug

    Specification: 3ml:2mg. Administered via nebulizer.

  • PlaceboOther

    Specification: 3ml:0mg. Matches the appearance of the investigation product. Administered via nebulizer.

  • Formoterol Fumarate Inhalation SolutionDrug

    Specification: 2ml:20μg. Administered via nebulizer.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From signing of informed consent through the safety follow-up visit (Day 21)

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Zhangzhou Hospital, Fujian Province

    Zhangzhou, Fujian, China

  • Guangzhou First People's Hospital

    Guangzhou, Guangdong, China

  • Liuyang People's Hospital

    Guankou, Hunan, China

  • Jiangyin Hospital of Traditional Chinese Medicine

    Jiangyin, Jiangsu, China

  • The Affiliated Hospital of Yangzhou University

    Yangzhou, Jiangsu, China

  • Weifang Second People's Hospital

    Weifang, Shandong, China

  • Huadong Hospital Affiliated to Fudan University

    Shanghai, Shanghai Municipality, China

  • Shanghai Pudong New Area People's Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.